Article
Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
The oncologist - 8 May 2023
Hou Zhiwei, Wu Huaguo, Luo Ningning, Li Shuo, Zhang Xiang, Dong Shuai, Zhu Dongyuan, Zhang Hui, Tao Rongjie
Abstract excerpt
Glioblastoma (GBM) is the most common primary brain tumor, and patients with GBM have a universally poor prognosis. Genomic profiling has detected epidermal growth factor receptor (EGFR) gene alterations in more than half of GBMs. Major genetic events include amplification and mutation of EGFR. Interestingly, we identified an EGFR p.L858R mutation in a patient with recurrent GBM for the first time. Based on the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.